TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[4-(3-CHLORO-4-FLUOROPHENYL)-1-(2-HYDROXYETHYL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE

TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 6-[4-(3-CHLORO-4-FLUOROPHENYL)-1-(2-HYDROXYETHYL)-1H-IMIDAZOL-5-YL]IMIDAZO[1,2-B]PYRIDAZINE-3-CARBONITRILE Descriptor: 6-[4-(3-chloro-4-fluorophenyl)-1-(2-hydroxyethyl)-1H-imidazol-5-yl]imidazo[1,2-b]pyridazine-3-carbonitrile, GLYCEROL, TGF-beta receptor type-1 Authors: Sheriff, S. Deposit date: 2019-11-19 Release date: 2020-02-05 Last modified: 2026-02-18 Method: X-RAY DIFFRACTION (1.67 Å) Cite: Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGF beta R1 Inhibitor as an Immuno-oncology Agent. Acs Med.Chem.Lett., 11, 2020

转化生长因子β（TGF-β）I型受体激酶结构域（T204D）与6-[4-(3-氯-4-氟苯基)-1-(2-羟乙基)-1H-咪唑-5-基]咪唑并[1,2-b]哒嗪-3-甲腈的复合物
描述项：6-[4-(3-氯-4-氟苯基)-1-(2-羟乙基)-1H-咪唑-5-基]咪唑并[1,2-b]哒嗪-3-甲腈、甘油、转化生长因子β受体I型（TGF-beta receptor type-1）
作者：Sheriff, S.
提交日期：2019-11-19
发布日期：2020-02-05
末次修改日期：2026-02-18
实验方法：X射线衍射（1.67 Å）
引用文献：《BMS-986260的发现：一种强效、选择性且口服生物可利用的TGFβR1抑制剂，作为肿瘤免疫治疗药物》，Acs Med.Chem.Lett., 11, 2020